Clinical Trial Update: Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating dendritic cell–based immunotherapy in combination with low-dose cyclophosphamide for malignant pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Dendritic cell-based immunotherapy

Snippet

Sponsor: Erasmus Medical Center | Conditions: Malignant (Pleural) Mesothelioma | Phase 1 | Status: COMPLETED